A Study of the Efficacy and Safety of Pregabalin for the Treatment of Diabetic Peripheral Neuropathy or Postherpetic Neuralgia

Back to Search
Print
Bookmark Trial

NCT00629681

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Aachen, , 52064, Germany
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Painful Diabetic Neuropathy and Post Herpetic Neuralgia
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Diagnosis of DPN or PHN

- Score on the Numeric Rating Scale of at least 4/10

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Hospitalized patients


- Neurologic disorders unrelated to DPN or PHN or any severe pain that may confound the
assessment of DPN- or PHN-related pain

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Painful Diabetic Neuropathy and Post Herpetic NeuralgiaA Study of the Efficacy and Safety of Pregabalin for the Treatment of Diabetic Peripheral Neuropathy or Postherpetic Neuralgia
NCT00629681
  1. Aachen,
  2. Albstadt,
  3. Berlin,
  4. Berlin,
  5. Berlin,
  6. Bielefeld,
  7. Celle,
  8. Deggingen,
  9. Duisburg,
  10. Erbach,
  11. Erfurt,
  12. Frankfurt,
  13. Gera,
  14. Goeppingen,
  15. Hamburg,
  16. Hamburg,
  17. Hamburg,
  18. Hemsbach,
  19. Hildesheim,
  20. Holle,
  21. Itzehoe,
  22. Karlsruhe,
  23. Karlsruhe,
  24. Katzhuette,
  25. Leer,
  26. Leipzig,
  27. Limburgerhof,
  28. Ludwigshafen,
  29. Ludwigshafen,
  30. Luebeck,
  31. Luenen,
  32. Mainz,
  33. Marl,
  34. Muenchen,
  35. Muenster,
  36. Osnabrueck,
  37. Recklinghausen,
  38. Senftenberg,
  39. Sinsheim,
  40. Surwold,
  41. Unterhaching,
  42. Veitsbronn,
  43. Weimar,
  44. Wiesbaden,
  45. Witten,
  46. Zwoenitz,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE A Study of the Efficacy and Safety of Pregabalin for the Treatment of Diabetic Peripheral Neuropathy or Postherpetic Neuralgia
Official Title  ICMJE Efficacy and Safety of Pregabalin in an Open-label, Non-comparative, Flexible-dose Trial With Diabetic Peripheral Neuropathy or Postherpetic Neuralgia
Brief Summary The purpose of this study is to assess the efficacy and safety of pregabalin for the treatment of diabetic peripheral neuropathy (DPN) or postherpetic neuralgia (PHN)
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Painful Diabetic Neuropathy and Post Herpetic Neuralgia
Intervention  ICMJE Drug: Pregabalin
Pregabalin capsules; initial dose of 75 mg twice daily for 4 days. Dose could be increased based on individual patient's response and tolerability to 150 mg twice daily from Day 4 onwards, with a further increase to 300 mg twice daily from Day 14 onwards if needed. Total duration of treatment was 28 days.
Study Arms  ICMJE Experimental: 1
Intervention: Drug: Pregabalin
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: April 22, 2011)		217
Original Estimated Enrollment  ICMJE
 (submitted: February 26, 2008)		300
Actual Study Completion Date  ICMJE February 2006
Primary Completion Date Not Provided
Eligibility Criteria  ICMJE

Inclusion criteria:

  • Diagnosis of DPN or PHN
  • Score on the Numeric Rating Scale of at least 4/10

Exclusion Criteria:

  • Hospitalized patients
  • Neurologic disorders unrelated to DPN or PHN or any severe pain that may confound the assessment of DPN- or PHN-related pain
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Germany
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00629681
Other Study ID Numbers  ICMJE A0081031
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Director, Clinical Trial Disclosure Group, Pfizer, Inc.
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date April 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP